Dataset Information

Management of hepatocellular carcinoma from diagnosis in routine clinical practice.

ABSTRACT:

Aim

To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network.

Materials & methods

A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient.

Results

Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72-82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy.

Conclusion

This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.

SUBMITTER: Lokhandwala T

PROVIDER: S-EPMC10064261 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Management of hepatocellular carcinoma from diagnosis in routine clinical practice.

Lokhandwala Tasneem T Aly Abdalla A Farrelly Eileen E Willey Joanne P JP Lamerato Lois E LE Healey Marcus M Coutinho Anna D AD Seal Brian S BS

Hepatic oncology 20221201 4

<h4>Aim</h4>To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network.<h4>Materials & methods</h4>A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient.<h4>Results</h4>Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment ...[more]

PMID: 37009420

Similar Datasets

Project description:IntroductionGlobally, the incidence, as well as mortality, related to hepatocellular carcinoma (HCC) is on the rise, owing to relatively few curative options. Underlying cirrhosis is the most common etiology leading to HCC, but risk factors of cirrhosis show great regional variability. Over the years, there has been a steady development in the diagnostic and therapeutic modalities of HCC, including the availability of a wide range of systemic chemotherapeutic agents. We aim to review the recent advancements in the diagnostic and therapeutic strategies for HCC.MethodologyThe literature search was done using databases PubMed, Cochrane, and Science Direct, and the latest relevant articles were reviewed.FindingsScreening of HCC is a pivotal step in the early diagnosis of the disease. Current guidelines recommend using ultrasound and alfa fetoprotein but various new biomarkers are under active research that might aid in diagnosing very small tumors, not picked up by the current screening methods. Treatment options are decided based upon the overall performance of the patient and the extent of the disease, as per the Barcelona classification. There are very few options that offer a cure for the disease, ranging from liver resection and transplantation to tumor ablation. Downstaging has proven to have a significant role in the course of the disease. An attempt to control the disease can be made via radiological interventions, such as transarterial chemoembolization, transarterial radioembolization, or radiation therapy. For advanced disease, sorafenib used to be the only option until a couple of years ago. Recently, many other systemic agents have received approval as first-line and second-line therapies for HCC. Genomics is an area of active clinical research as understanding the mutations and genomics involved in the evolution of HCC might lead to a breakthrough therapy.How to cite this articleRaees A, Kamran M, Özkan H, et al. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepato-Gastroenterol 2021;11(1):32-40.

Dataset Information

Management of hepatocellular carcinoma from diagnosis in routine clinical practice.

Aim

Materials & methods

Results

Conclusion

Publications

Management of hepatocellular carcinoma from diagnosis in routine clinical practice.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets